AIMD Stock Overview
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Ainos, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.01 |
| 52 Week High | US$6.10 |
| 52 Week Low | US$0.79 |
| Beta | 1.47 |
| 1 Month Change | -22.31% |
| 3 Month Change | -2.88% |
| 1 Year Change | -74.10% |
| 3 Year Change | -98.02% |
| 5 Year Change | -96.63% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt
Mar 10
Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt
Aug 28Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt
May 15Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19
Sep 30Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19
Aug 24Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M
Aug 15Shareholder Returns
| AIMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.0% | -2.5% | -3.2% |
| 1Y | -74.1% | -3.7% | 19.3% |
Return vs Industry: AIMD underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: AIMD underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| AIMD volatility | |
|---|---|
| AIMD Average Weekly Movement | 29.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AIMD's share price has been volatile over the past 3 months.
Volatility Over Time: AIMD's weekly volatility has increased from 22% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 46 | Chun-Hsien Tsai | www.ainos.com |
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products.
Ainos, Inc. Fundamentals Summary
| AIMD fundamental statistics | |
|---|---|
| Market cap | US$6.01m |
| Earnings (TTM) | -US$13.77m |
| Revenue (TTM) | US$122.11k |
49.2x
P/S Ratio-0.4x
P/E RatioIs AIMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIMD income statement (TTM) | |
|---|---|
| Revenue | US$122.11k |
| Cost of Revenue | US$375.85k |
| Gross Profit | -US$253.73k |
| Other Expenses | US$13.52m |
| Earnings | -US$13.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.31 |
| Gross Margin | -207.79% |
| Net Profit Margin | -11,276.98% |
| Debt/Equity Ratio | 23.3% |
How did AIMD perform over the long term?
See historical performance and comparison